Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR)
The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2×/day) or lamivudine (150 mg 2×/day) plus lovi...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1999-09, Vol.180 (3), p.607-613 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 613 |
|---|---|
| container_issue | 3 |
| container_start_page | 607 |
| container_title | The Journal of infectious diseases |
| container_volume | 180 |
| creator | Dore, Gregory J. Cooper, David A. Barrett, Catherine Goh, Li-Ean Thakrar, Bharat Atkins, Mark |
| description | The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2×/day) or lamivudine (150 mg 2×/day) plus loviride (100 mg 3×/day) to zidovudine-containing background antiretroviral treatment. Baseline hepatitis B surface antigen (HBsAg) results were available for 1790 study subjects, of whom 122 (6.8%) tested positive. Retrospective analyses for serial HBV DNA, HBsAg, and hepatitis B e antigen (HBeAg) were performed on stored sera from 118 HBsAg-positive subjects. HBV DNA and HBeAg were present in 83% and 63%, respectively. At weeks 12 and 52, median log10 HBV DNA change was −2.0 and −2.7, respectively, in the lamivudine arms, compared with no reduction among placebo recipients (P < .001). A trend to lower alanine transferase level, and delayed progression of HIV-1 disease (relative hazard, 0.26; 95% confidence interval, 0.08–0.80) were also seen in the lamivudine arms, compared with the placebo group. |
| doi_str_mv | 10.1086/314942 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17895645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30111066</jstor_id><sourcerecordid>30111066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-c34d0ded9ed82d4ecc8ba20963ef84c2851088a5fff56503eb31d93ee606e1683</originalsourceid><addsrcrecordid>eNpdkd-K1DAUxosoOK76BkIQEQXrJk2TtpdjHe3igO4fF5mbkE1OIGObjEkqjlc-hOD7-SR26LILXh043-9853C-LHtM8GuCa35MSdmUxZ1sQRitcs4JvZstMC6KnNRNcz97EOMWY1xSXi2yP29H2aOVMVZJtUfeoLUc7PdRWwfoIoBMA7iErEPdOEiHToZhdF7DxFtw08SlDWM87mAnk002ojdz5--v3623zoBKoNEnCNG7eLCR6Ew67Qf7E_Qr1HqXgu_7iTlPo96jF-1ydb48e_kwu2dkH-HRdT3KPr9bXbRdvv74_qRdrnNVYpxyRUuNNegGdF3oEpSqr2SBG07B1KUqaja9pJbMGMM4wxSuKNENBeCYA-E1Pcqez7674L-NEJMYbFTQ99KBH6MgVd0wXrIJfPofuPVjcNNtoihogxll_NZNBR9jACN2wQ4y7AXB4hCOmMOZwGfXbjIq2ZsgnbLxlm4IZ8Vh6ZMZ28bkw41MMSEE88O-fNZtTPDjRpfhq-AVrZjovmwE2ZxebrrTD6Kg_wCL6Kfd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223905356</pqid></control><display><type>article</type><title>Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR)</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Dore, Gregory J. ; Cooper, David A. ; Barrett, Catherine ; Goh, Li-Ean ; Thakrar, Bharat ; Atkins, Mark</creator><creatorcontrib>Dore, Gregory J. ; Cooper, David A. ; Barrett, Catherine ; Goh, Li-Ean ; Thakrar, Bharat ; Atkins, Mark ; CAESAR Coordinating Committee</creatorcontrib><description>The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2×/day) or lamivudine (150 mg 2×/day) plus loviride (100 mg 3×/day) to zidovudine-containing background antiretroviral treatment. Baseline hepatitis B surface antigen (HBsAg) results were available for 1790 study subjects, of whom 122 (6.8%) tested positive. Retrospective analyses for serial HBV DNA, HBsAg, and hepatitis B e antigen (HBeAg) were performed on stored sera from 118 HBsAg-positive subjects. HBV DNA and HBeAg were present in 83% and 63%, respectively. At weeks 12 and 52, median log10 HBV DNA change was −2.0 and −2.7, respectively, in the lamivudine arms, compared with no reduction among placebo recipients (P < .001). A trend to lower alanine transferase level, and delayed progression of HIV-1 disease (relative hazard, 0.26; 95% confidence interval, 0.08–0.80) were also seen in the lamivudine arms, compared with the placebo group.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/314942</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>AIDS ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Disease progression ; Experimentation ; Hepatitis antigens ; Hepatitis B ; Hepatitis B virus ; HIV ; HIV 1 ; Human immunodeficiency virus 1 ; Human viral diseases ; Infections ; Infectious diseases ; Major Articles ; Medical sciences ; Pharmacology. Drug treatments ; Placebos ; Viral diseases ; Viral hepatitis ; Viruses</subject><ispartof>The Journal of infectious diseases, 1999-09, Vol.180 (3), p.607-613</ispartof><rights>Copyright 1999 Infectious Diseases Society of America</rights><rights>1999 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Sep 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-c34d0ded9ed82d4ecc8ba20963ef84c2851088a5fff56503eb31d93ee606e1683</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30111066$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30111066$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1916525$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Dore, Gregory J.</creatorcontrib><creatorcontrib>Cooper, David A.</creatorcontrib><creatorcontrib>Barrett, Catherine</creatorcontrib><creatorcontrib>Goh, Li-Ean</creatorcontrib><creatorcontrib>Thakrar, Bharat</creatorcontrib><creatorcontrib>Atkins, Mark</creatorcontrib><creatorcontrib>CAESAR Coordinating Committee</creatorcontrib><title>Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR)</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><description>The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2×/day) or lamivudine (150 mg 2×/day) plus loviride (100 mg 3×/day) to zidovudine-containing background antiretroviral treatment. Baseline hepatitis B surface antigen (HBsAg) results were available for 1790 study subjects, of whom 122 (6.8%) tested positive. Retrospective analyses for serial HBV DNA, HBsAg, and hepatitis B e antigen (HBeAg) were performed on stored sera from 118 HBsAg-positive subjects. HBV DNA and HBeAg were present in 83% and 63%, respectively. At weeks 12 and 52, median log10 HBV DNA change was −2.0 and −2.7, respectively, in the lamivudine arms, compared with no reduction among placebo recipients (P < .001). A trend to lower alanine transferase level, and delayed progression of HIV-1 disease (relative hazard, 0.26; 95% confidence interval, 0.08–0.80) were also seen in the lamivudine arms, compared with the placebo group.</description><subject>AIDS</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Disease progression</subject><subject>Experimentation</subject><subject>Hepatitis antigens</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>HIV</subject><subject>HIV 1</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Major Articles</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpdkd-K1DAUxosoOK76BkIQEQXrJk2TtpdjHe3igO4fF5mbkE1OIGObjEkqjlc-hOD7-SR26LILXh043-9853C-LHtM8GuCa35MSdmUxZ1sQRitcs4JvZstMC6KnNRNcz97EOMWY1xSXi2yP29H2aOVMVZJtUfeoLUc7PdRWwfoIoBMA7iErEPdOEiHToZhdF7DxFtw08SlDWM87mAnk002ojdz5--v3623zoBKoNEnCNG7eLCR6Ew67Qf7E_Qr1HqXgu_7iTlPo96jF-1ydb48e_kwu2dkH-HRdT3KPr9bXbRdvv74_qRdrnNVYpxyRUuNNegGdF3oEpSqr2SBG07B1KUqaja9pJbMGMM4wxSuKNENBeCYA-E1Pcqez7674L-NEJMYbFTQ99KBH6MgVd0wXrIJfPofuPVjcNNtoihogxll_NZNBR9jACN2wQ4y7AXB4hCOmMOZwGfXbjIq2ZsgnbLxlm4IZ8Vh6ZMZ28bkw41MMSEE88O-fNZtTPDjRpfhq-AVrZjovmwE2ZxebrrTD6Kg_wCL6Kfd</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Dore, Gregory J.</creator><creator>Cooper, David A.</creator><creator>Barrett, Catherine</creator><creator>Goh, Li-Ean</creator><creator>Thakrar, Bharat</creator><creator>Atkins, Mark</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19990901</creationdate><title>Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR)</title><author>Dore, Gregory J. ; Cooper, David A. ; Barrett, Catherine ; Goh, Li-Ean ; Thakrar, Bharat ; Atkins, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-c34d0ded9ed82d4ecc8ba20963ef84c2851088a5fff56503eb31d93ee606e1683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>AIDS</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Disease progression</topic><topic>Experimentation</topic><topic>Hepatitis antigens</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>HIV</topic><topic>HIV 1</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Major Articles</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dore, Gregory J.</creatorcontrib><creatorcontrib>Cooper, David A.</creatorcontrib><creatorcontrib>Barrett, Catherine</creatorcontrib><creatorcontrib>Goh, Li-Ean</creatorcontrib><creatorcontrib>Thakrar, Bharat</creatorcontrib><creatorcontrib>Atkins, Mark</creatorcontrib><creatorcontrib>CAESAR Coordinating Committee</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dore, Gregory J.</au><au>Cooper, David A.</au><au>Barrett, Catherine</au><au>Goh, Li-Ean</au><au>Thakrar, Bharat</au><au>Atkins, Mark</au><aucorp>CAESAR Coordinating Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR)</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>The Journal of Infectious Diseases</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>180</volume><issue>3</issue><spage>607</spage><epage>613</epage><pages>607-613</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2×/day) or lamivudine (150 mg 2×/day) plus loviride (100 mg 3×/day) to zidovudine-containing background antiretroviral treatment. Baseline hepatitis B surface antigen (HBsAg) results were available for 1790 study subjects, of whom 122 (6.8%) tested positive. Retrospective analyses for serial HBV DNA, HBsAg, and hepatitis B e antigen (HBeAg) were performed on stored sera from 118 HBsAg-positive subjects. HBV DNA and HBeAg were present in 83% and 63%, respectively. At weeks 12 and 52, median log10 HBV DNA change was −2.0 and −2.7, respectively, in the lamivudine arms, compared with no reduction among placebo recipients (P < .001). A trend to lower alanine transferase level, and delayed progression of HIV-1 disease (relative hazard, 0.26; 95% confidence interval, 0.08–0.80) were also seen in the lamivudine arms, compared with the placebo group.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><doi>10.1086/314942</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1999-09, Vol.180 (3), p.607-613 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17895645 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current) |
| subjects | AIDS Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Disease progression Experimentation Hepatitis antigens Hepatitis B Hepatitis B virus HIV HIV 1 Human immunodeficiency virus 1 Human viral diseases Infections Infectious diseases Major Articles Medical sciences Pharmacology. Drug treatments Placebos Viral diseases Viral hepatitis Viruses |
| title | Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus—Coinfected Persons in a Randomized, Controlled Study (CAESAR) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A24%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20Efficacy%20of%20Lamivudine%20Treatment%20in%20Human%20Immunodeficiency%20Virus/Hepatitis%20B%20Virus%E2%80%94Coinfected%20Persons%20in%20a%20Randomized,%20Controlled%20Study%20(CAESAR)&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Dore,%20Gregory%20J.&rft.aucorp=CAESAR%20Coordinating%20Committee&rft.date=1999-09-01&rft.volume=180&rft.issue=3&rft.spage=607&rft.epage=613&rft.pages=607-613&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/314942&rft_dat=%3Cjstor_proqu%3E30111066%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223905356&rft_id=info:pmid/&rft_jstor_id=30111066&rfr_iscdi=true |